National Lung Cancer Audit annual report 2017 | The Healthcare Quality Improvement Partnership
This is the 13th annual report on the clinical component (process of care) of the National Lung Cancer Audit. It contains national and named team results on the quality of lung cancer care for patients diagnosed between 1 January and 31 December 2016 and covers many processes of care across the entire patient pathway.
Targeted audiences who will benefit from reading the findings of this report include NHS staff in lung cancer multidisciplinary teams; hospital managers and chief executives; commissioners; lung cancer researchers; lung cancer patients their families and their carers who may use the findings to inform their care decisions.
NHS England announces the scaling up of an innovative scheme that catches lung cancer early by scanning patients, along with new details of a more sensitive bowel cancer test that could save thousands of lives.
NHS England is now funding scanners in other areas as part of a national programme to diagnose cancer earlier, improve the care for those living with cancer and ensure each cancer patient gets the right care for them. This follows the success of the Manchester scanner scheme, where mobile scanners are detecting four out of five cases of lung cancer in the early stages when it is easier to treat. The mobile scanning trucks have picked up one cancer for every 33 patients scanned over the course of a year.
Plans for ‘FIT’, a more sensitive bowel cancer test that could see as many as 1,500 more cancer caught earlier every year have also been confirmed.
‘FIT’ is an easy to use home testing kit which predicts bowel cancer, following the introduction of the test almost a third of a million more people are expected to complete screening. The sensitivity level determines the number of people who should go on for further cancer testing.
National Lung Cancer Audit 2016: Key findings for patients and carers | The Healthcare Quality Improvement Partnership
The information in this booklet aimed at patients and carers is a summary of key results from the 2016 National Lung Cancer Audit (NLCA) annual report, which looked at patients diagnosed from 1 January to 31 December 2015. This booklet specifically looks at how the organisation performed in key areas of the patient pathway. It does not include information on the types of treatment or drugs available to lung cancer patients.
Neal, R.D. et al. (2017) British Journal of Cancer. 116, pp. 293-302
Background: Achieving earlier stage diagnosis is one option for improving lung cancer outcomes in the United Kingdom. Patients with lung cancer typically present with symptoms to general practitioners several times before referral or investigation.
Conclusions: We have demonstrated the feasibility of individually randomising patients at higher risk of lung cancer, to a trial offering urgent investigation or usual care.
Guillon, A. et al. Critical Care. Published online: 27 January 2017
Bald heads may soon not be a sign that identifies a cancer patient receiving treatment. Indeed, therapies for cancer patients are improving dramatically leading to increased survival rates, and most are associated with a different toxicity profile. Recently, antibody-based therapy has transformed the therapeutic landscape and biology of non-small cell lung cancer (NSCLC) and other solid tumors. This may also reshuffle the playing cards for an intensive care unit (ICU) admission policy due to improved outcomes.
In November 2016, the results of the KEYNOTE-024 trial showed for the first time the superiority of immunotherapy over chemotherapy as first-line treatment for NSCLC . In this phase 3 trial, a humanized monoclonal antibody (mAb) against programmed death 1 (PD-1) was tested in patients who had previously untreated advanced NSCLC. The clinical trial was stopped by the safety monitoring committee on the basis of substantial clinical benefit of immunotherapy, and patients remaining in the chemotherapy group were switched to receive immunotherapy.
The National Lung Cancer Audit annual report 2016, commissioned by the Healthcare Quality Improvement Partnership (HQIP), shows an encouraging rise in survival as more patients receive life-prolonging treatments.
The report covers patients with lung cancer first diagnosed in 2015. It says there was a 7% increase in the number of people diagnosed with lung cancer surviving for longer than one year – rising from 31% to 38% in the five-year period from 2010 to 2015.
In addition, 60% of lung cancer patients received anti-cancer treatment such as chemotherapy, radiotherapy or surgery, meeting the target set out in the 2015 annual audit report.
This is the 12th report on the clinical component (process of care) of the National Lung Cancer Audit. It publishes national and named team results on the quality of lung cancer care for patients diagnosed between 1 January and 31 December 2015. The key findings include a 7% rise in one-year survivorship since 2010.